The Branch-based Intraoperative Stent System in the Treatment of Stanford A Aortic Dissection（BROAD）

Inclusion Criteria: 1. Age ≥ 18 and ≤ 75 years, male or female; 2. Stanford type A aortic dissection subjects with involvement of the descending arch aorta； 3. Subjects treated with stent pictorial procedures as judged appropriate by the investigator； 4. Subjects or their legal surrogates were able to understand the purpose of the study, had adequate compliance to the clinical study protocol, and voluntarily signed the informed consent form. Exclusion Criteria: 1. Subjects with aortic dissections confined to the ascending and / or arch 2. Subjects with a left common carotid artery branch vessel diameter \< 5 mm or \> 16 mm (not applicable to subjects enrolled with a single branch structure) 3. Subjects with a left subclavian artery branch vessel diameter \< 7 mm or \> 16 mm 4. Subjects with aortic dissection with severe malperfusion syndrome preoperatively (e.g., subjects presenting with coma, paraplegia, need for dialysis, gastrointestinal necrosis or limb necrosis due to ischemia, etc.) 5. Subjects with vertebral artery variants 6. Subjects with infectious aortic dissections 7. Subjects with acute systemic infection, severe infection and associated sepsis, shock or multiple organ failure 8. Subjects unable to tolerate anaesthesia and cardiopulmonary bypass 9. Subjects who had undergone open surgical procedures of the cardiocerebral vasculature within 90 days prior to surgery 10. Subjects with history of active bleeding, coagulopathy or refusal of blood transfusion 11. Subjects known to be allergic to materials such as contrast agents, nitinol alloys, coated artificial blood vessels 12. Subjects with a life expectancy of less than 12 months (other than disease due to aortic dissection) 13. Subjects being enrolled in other clinical trials 14. Pregnant and lactating women, and subjects with a recent pregnancy preparation 15. Subjects with poor compliance other conditions that the investigator considers inappropriate for participation in the clinical trial.